During REM sleep, the body enters a state of paralysis. This can pose a danger for patients with weakened diaphragms due to neuromuscular diseases.

CRISPR-edited iPSCs uncover early mitochondrial defects shared across ALS mutations, revealing pathways that could guide future treatments.

Patients with less neuronal damage, determined by low spinal fluid pNFH, had a 48% reduction in the risk of death by adding IL-2 to riluzole.